<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704792</url>
  </required_header>
  <id_info>
    <org_study_id>M134</org_study_id>
    <nct_id>NCT03704792</nct_id>
  </id_info>
  <brief_title>Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference</brief_title>
  <official_title>Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Echosens</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Echosens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic liver diseases (CLDs) represent a major worldwide public health burden. Worldwide&#xD;
      estimations show that 844 million people have CLDs, a lot more than other chronic diseases&#xD;
      such as diabetes or cardiovascular diseases. CLD is most of the time an asymptomatic,&#xD;
      progressive, and potentially fatal disease. With its complications it becomes one of the&#xD;
      major causes of mortality worldwide. Globally, hepatitis B virus and hepatitis C virus,&#xD;
      alcoholic liver disease and non-alcoholic steatohepatitis, are the most important causes of&#xD;
      liver disease.&#xD;
&#xD;
      The diagnosis of liver lesions remains an important issue for these patients. The prognosis&#xD;
      and management of liver disease greatly depends on the amount of liver fibrosis. In early&#xD;
      stages, it is the main factor predicting long-term outcome of these patients. The liver&#xD;
      biopsy still represents the gold standard diagnostic tool for liver fibrosis assessment,&#xD;
      although a wide spectrum of noninvasive tools are now commonly used as a surrogate to the&#xD;
      liver biopsy. It includes direct and indirect serum markers of liver fibrosis, but also&#xD;
      several imaging-based methods, including transient elastography (FibroScan®, Echosens, Paris,&#xD;
      France).&#xD;
&#xD;
      Even if the liver fibrosis is the key pathological feature of progressive liver disease, the&#xD;
      accumulation of excessive hepatic triglyceride, hepatic steatosis, is today recognized as an&#xD;
      important factor in the pathogenesis of a number of CLD. The magnetic resonance imaging (MRI)&#xD;
      techniques are sensitive to steatosis and show interesting diagnostic performances,&#xD;
      especially the MRI using the proton density fat fraction (MRI-PDFF) which has shown at least&#xD;
      equivalence in accuracy for quantifying hepatic steatosis with both 1H Magnetic Resonance&#xD;
      Spectroscopy and with histological grade, across several studies. Therefore, this technique&#xD;
      is now part of the gold standard diagnostic tool to establish the grade of hepatic steatosis.&#xD;
      Echosens has developed an ultrasonic controlled attenuation parameter (CAP) designed to&#xD;
      quantify hepatic steatosis using a process based on vibration controlled transient&#xD;
      elastography (VCTE™).&#xD;
&#xD;
      Echosens is working on improving the diagnostic accuracy of the CAP measurement performed&#xD;
      with the FibroScan. This protocol is set-up to compare the diagnostic performances of the&#xD;
      first generation of the CAP and the second generation of the CAP to the reference, the&#xD;
      MRI-PDFF, in patients with CLD, all etiologies combined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fat content assessed by MRI-PDFF.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio IQR CAPv1/CAPv2 and/or ratio standard deviation CAPv1/CAPv2</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between CAPv1 and CAPv2 measures</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between CAPv1, CAPv2 and MRI-PDFF</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Adult CLD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only one group of patients in the study: adult patients with chronic liver disease (CLD), all etiologies combined, who will have a FibroScan 530 Compact examination to calculate the CAP value.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan 530 Compact</intervention_name>
    <description>The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.</description>
    <arm_group_label>Adult CLD Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be at least 18 years of age&#xD;
&#xD;
          -  Patient must be able to give written informed consent&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Patient with a chronic liver disease, all etiologies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vulnerable patient&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patient with presence of ascites&#xD;
&#xD;
          -  Contra-indication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Boursier, Pr</last_name>
      <phone>02 41 35 31 42</phone>
      <email>JeBoursier@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Paris Seine Saint-Denis - Service Hépatologie</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Ganne-Carrié, Pr.</last_name>
      <phone>33 1 48 02 62 80</phone>
      <email>nathalie.ganne@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor De Lédinghen, Pr</last_name>
      <phone>05 57 65 64 39</phone>
      <email>victor.deledinghen@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine - Service Hépatologie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Chazouillères, Pr.</last_name>
      <phone>33 1 49 28 23 78</phone>
      <email>olivier.chazouilleres@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes Hôpital Pontchaillou - Service des Maladies du Foie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Bardou-Jacquet, Pr.</last_name>
      <phone>33 2 99 28 42 98</phone>
      <email>edouard.bardou-jacquet@univ-rennes1.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

